Last reviewed · How we verify
Fluconazole capsule
Fluconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.
Fluconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Candidiasis (oropharyngeal, esophageal, vaginal, and systemic), Cryptococcal meningitis, Fungal prophylaxis in immunocompromised patients.
At a glance
| Generic name | Fluconazole capsule |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Triazole antifungal |
| Target | Fungal cytochrome P450 (lanosterol 14α-demethylase) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Fluconazole is a triazole antifungal that selectively binds to fungal cytochrome P450 enzymes, blocking the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disruption leads to increased membrane permeability and cell death. The drug has broad-spectrum activity against many Candida species, Cryptococcus, and other fungi.
Approved indications
- Candidiasis (oropharyngeal, esophageal, vaginal, and systemic)
- Cryptococcal meningitis
- Fungal prophylaxis in immunocompromised patients
- Other invasive fungal infections
Common side effects
- Headache
- Nausea
- Abdominal pain
- Diarrhea
- Rash
- Elevated liver enzymes
- Stevens-Johnson syndrome
Key clinical trials
- The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study (NA)
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. (PHASE3)
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (PHASE1, PHASE2)
- PTX3-targeted Antifungal Prophylaxis (NA)
- Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease (PHASE3)
- Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride (PHASE1)
- A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients (PHASE2)
- A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluconazole capsule CI brief — competitive landscape report
- Fluconazole capsule updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI